http://rdf.ncbi.nlm.nih.gov/pubchem/patent/CN-110036023-B
Outgoing Links
| Predicate | Object |
|---|---|
| classificationCPCAdditional | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K38-00 |
| classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K38-1709 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K38-17 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K14-47 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K14-4702 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P19-02 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K38-17 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07K14-47 |
| filingDate | 2017-11-09-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| grantDate | 2023-01-10-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationDate | 2023-01-10-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | CN-110036023-B |
| titleOfInvention | Nkx3.2 fragment and pharmaceutical composition comprising it as active ingredient |
| abstract | The present invention relates to Nkx3.2 fragments having improved stability in the histopathological context of arthritis and pharmaceutical compositions containing them as active ingredients. The Nkx3.2 fragment of the present invention has the function of activating NF-κB at a level similar to that of the full-length Nkx3.2 and the resistance of Siah1 to proteolysis. In addition, in the in vivo efficacy evaluation based on animal models, compared with Nkx3.2, the Nkx3.2 fragment has at least 10-fold improvement in the therapeutic effect on degenerative arthritis. Therefore, Nkx3.2 fragments can be advantageously used in the prevention or treatment of arthritis. |
| priorityDate | 2016-11-09-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 554.